Insmed director McGirr to step down after 2026 meeting
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Insmed ( (INSM) ) has provided an update.
On February 17, 2026, director David W.J. McGirr informed Insmed’s board that he will not stand for re-election at the 2026 annual meeting, though he will remain on the board and continue chairing the audit committee until then, and the company said his departure is not related to any disagreement. For 2025, Insmed reported total revenues of $606.4 million, including $433.8 million from ARIKAYCE, which grew 19% year over year and exceeded guidance, and $172.7 million from BRINSUPRI, while ending the year with about $1.4 billion in cash and equivalents.
Management highlighted strong early uptake of BRINSUPRI following its November 2025 approval in Europe for non-cystic fibrosis bronchiectasis and projected at least $1 billion in BRINSUPRI revenue in 2026, alongside reiterating 2026 ARIKAYCE guidance of $450 million to $470 million. The company also advanced a broad pipeline, securing U.S. orphan drug designation for TPIP’s active ingredient treprostinil palmitil in pulmonary arterial hypertension, progressing multiple Phase 3 respiratory studies and gene therapy programs in Duchenne muscular dystrophy and ALS, and preparing new trials and regulatory filings that could expand its presence across respiratory, immunology, and rare disease markets.
The most recent analyst rating on (INSM) stock is a Buy with a $211.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
The score is held back most by weak profitability and negative operating cash flow, alongside bearish technicals (below key moving averages and negative MACD). These are partially offset by strong commercial and pipeline momentum from the latest earnings call and corporate updates (BRINSUPRI launch traction, raised/beat revenue guidance, and EU approval), while valuation is mixed due to losses and no dividend support.
To see Spark’s full report on INSM stock, click here.
More about Insmed
Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing first- and best-in-class therapies for patients with serious and rare diseases, with a particular emphasis on respiratory conditions. Its key marketed products include BRINSUPRI for non-cystic fibrosis bronchiectasis and ARIKAYCE for Mycobacterium avium complex lung disease, complemented by an expanding pipeline in pulmonary hypertension, immunology, gene therapy, and other rare disorders.
Average Trading Volume: 3,083,014
Technical Sentiment Signal: Buy
Current Market Cap: $32.1B
See more data about INSM stock on TipRanks’ Stock Analysis page.
